|
|
|
|
||
Significant research showing benefit of EPA in reducing atherogenic processes just publishedVery significant research by Mason and Jacob (Harvard) just published. (From Ihub, where it was said this came from Amarin's website): My take: This is part of the
work first made public by Mason and Jacob at the NLA Scientific Sessions I attended in May 2014 and about which I was so excited. They told me then that their work would be published. Here it is! This is really important research, as it does provide scientific documentation, at the cellular level, for how EPA works differently than other TG lowering agents and thereby appears to inhibit atherogenic processes. This work demonstrates why it is reasonable to use EPA's beneficial activity in lipid management as a surrogate marker for CVD risk reduction, the principle that underlies the ANCHOR SPA. This work shows that FDA's (unsupported) position that using lipid management properties (beyond lowering LDL-C) as a surrogate marker is unlikely to be scientifically valid is incorrect, at least when EPA used in combination with atorvastatin is concerned. I.e., this is one more piece, and a very important one at that, of evidence showing the contrary of FDA's position. Everybody who can should be bombarding the FDA and politicians with this. As well, insurance companies should be being asked why they are reimbursing for Lovaza, but not Vascepa, when Vascepa is clearly a safer and more efficacious product that obviously does much more to inhibit CVD than does Lovaza. Patients will be less likely to develop CVD. Saves lives. Reduces costs of care. If nothing else, imo, this bodes well for REDUCE-IT (and in the meantime, CHERRY) to show clinical benefit resulting from EPA. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1682 | Re: Significant research showing benefit of EPA in reducing atherogenic processes just published | rosemountbomber | 1 | 12/4/2014 7:05:44 AM |